 Connection
Bryan Bergman to Lung Neoplasms
This is a "connection" page, showing publications Bryan Bergman has written about Lung Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.134 |
|
|
|
-
Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Lung Cancer. 2022 09; 171:103-114.
Score: 0.076
-
Gezelius E, Flou Kristensen A, Bendahl PO, Hisada Y, Risom Kristensen S, Ek L, Bergman B, Wallberg M, Falkmer U, Mackman N, Pedersen S, Belting M. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. PLoS One. 2018; 13(11):e0207387.
Score: 0.059
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|